Protein kinase C beta II suppresses colorectal cancer by regulating IGF-1 mediated cell survival

Oncotarget

Volumn 7, Issue 15, 2016, Pages 20919-20933

  Dowling, Catríona M ^a   Phelan, James ^b   Callender, Julia A ^c   Cathcart, Mary Clare ^b   Mehigan, Brian ^d   McCormick, Paul ^d   Dalton, Tara ^a   Coffey, John C ^e   Newton, Alexandra C ^c   O'Sullivan, Jacintha ^b   Kiely, Patrick A ^a  

^a UNIVERSITY OF LIMERICK   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ST JAMES S HOSPITAL   (Ireland)

^e UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

Cell survival; Colorectal cancer; IGF 1; Protein kinase C; Tumour suppressor

Indexed keywords

PROTEIN KINASE C BETA II; SOMATOMEDIN C; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; PROTEIN KINASE C BETA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PHENOTYPE; PKC BETA II GENE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; APOPTOSIS; CELL MOTION; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG EFFECTS; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR CELL CULTURE; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BIOMARKERS, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROTEIN KINASE C BETA; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED;

EID: 84964713813     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8062     Document Type: Article

References (56)

1. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem. 1982; 257:7847-7851.
2. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer. 2007; 7:281-294.
3. Martiny-Baron G, Fabbro D. Classical PKC isoforms in cancer. Pharmacol Res. 2007; 55:477-486.
4. Toton E, Ignatowicz E, Skrzeczkowska K, Rybczynska M. Protein kinase Ce as a cancer marker and target for anticancer therapy. Pharmacol Rep. 2011; 63:19-29.
5. Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov. 2012; 11:937-957.
6. Newton AC. Protein kinase C: structure, function, and regulation. J Biol Chem. 1995; 270:28495-28498.
7. Newton AC. Protein kinase C: poised to signal. Am J Physiol Endocrinol Metab. 2010; 298:E395-E402.
8. Steinberg SF. Structural basis of protein kinase C isoform function. Physiol Rev. 2008; 88:1341-1378.
9. Rosse C, Linch M, Kermorgant S, Cameron AJ, Boeckeler K, Parker PJ. PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol. 2010; 11:103-112.
10. Antal CE, Violin JD, Kunkel MT, Skovsø S, Newton AC. Intramolecular conformational changes optimize protein kinase C signaling. Chem Biol. 2014; 21:459-469.
11. Behn-Krappa A, Newton AC. The hydrophobic phosphorylation motif of conventional protein kinase C is regulated by autophosphorylation. Curr Biol. 1999; 9:728-737.
12. Newton A. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J. 2003; 370:361-371.
13. Seki T, Matsubayashi H, Amano T, Shirai Y, Saito N, Sakai N. Phosphorylation of PKC activation loop plays an important role in receptor-mediated translocation of PKC. Genes Cells. 2005; 10:225-239.
14. Dutil EM, Newton AC. Dual role of pseudosubstrate in the coordinated regulation of protein kinase C by phosphorylation, diacylglycerol. J Biol Chem. 2000; 275:10697-10701.
15. Newton AC, Johnson JE. Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. BBA-Rev Biomembranes. 1998; 1376:155-172.
16. Hansra G, Bornancin F, Whelan R, Hemmings BA, Parker PJ. 12-O-Tetradecanoylphorbol-13-acetate-induced dephosphorylation of protein kinase Ca correlates with the presence of a membrane-associated protein phosphatase 2A heterotrimer. J Biol Chem. 1996; 271:32785-32788.
17. Young S, Parker P, Ullrich A, Stabel S. Down-regulation of protein kinase C is due to an increased rate of degradation. Biochem J. 1987; 244:775-779.
18. Lu Z, Liu D, Hornia A, Devonish W, Pagano M, Foster DA. Activation of protein kinase C triggers its ubiquitination, degradation. Mol Cell Biol. 1998; 18:839-845.
19. RON D, KAZANIETZ MG. New insights into the regulation of protein kinase C, novel phorbol ester receptors. FASEB J. 1999; 13:1658-1676.
20. Blobe GC, Obeid LM, Hannun YA. Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev. 1994; 13:411-431.
21. Krasnitsky E, Baumfeld Y, Freedman J, Sion-Vardy N, Ariad S, Novack V, Livneh E. PKCη is a novel prognostic marker in non-small cell lung cancer. Anticancer Res. 2012; 32:1507-1513.
22. Kim K-M, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, Jeong JS, Cho M-Y, Jin S-Y, Choi JS. PKCη expression in gastrointestinal stromal tumor. Mod Pathol. 2006; 19:1480-1486.
23. Bosco R, Melloni E, Celeghini C, Rimondi E, Vaccarezza M, Zauli G. Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. Mini Rev Med Chem. 2011; 11:185-199.
24. Koivunen J, Aaltonen V, Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett. 2006; 235:1-10.
25. Wu B, Zhou H, Hu L, Mu Y, Wu Y. Involvement of PKCa activation in TF/VIIa/PAR2-induced proliferation, migration, and survival of colon cancer cell SW620. Tumor Biol. 2013; 34:837-846.
26. Gwak J, Jung SJ, Kang DI, Kim EY, Kim DE, Chung YH, Shin JG, Oh S. Stimulation of protein kinase C-a suppresses colon cancer cell proliferation by down-regulation of β-catenin. J Cell Mol Med. 2009; 13:2171-2180.
27. Luna-Ulloa LB, Hernández-Maqueda JG, Santoyo-Ramos P, Castañeda-Patlán MC, Robles-Flores M. Protein kinase C ζ is a positive modulator of canonical Wnt signaling pathway in tumoral colon cell lines. Carcinogenesis. 2011:bgr190.
28. Ma L, Tao Y, Duran A, Llado V, Galvez A, Barger JF, Castilla EA, Chen J, Yajima T, Porollo A. Control of nutrient stress-induced metabolic reprogramming by PKCη in tumorigenesis. Cell. 2013; 152:599-611.
29. Li H, Weinstein IB. Protein kinase C β enhances growth and expression of cyclin D1 in human breast cancer cells. Cancer Res. 2006; 66:11399-11408.
30. Urtreger AJ, Kazanietz MG, Bal de Kier Joffé ED. Contribution of individual PKC isoforms to breast cancer progression. IUBMB Life. 2012; 64:18-26.
31. Grossoni VC, Todaro LB, Kazanietz MG, de Kier Joffé EDB, Urtreger AJ. Opposite effects of protein kinase C beta1 (PKCβ1) and PKCe in the metastatic potential of a breast cancer murine model. Breast Cancer Res Treat. 2009; 118:469-480.
32. Gökmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP. Elevated protein kinase C βII is an early promotive event in colon carcinogenesis. Cancer Res. 2001; 61:1375-1381.
33. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE. The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615. HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005; 65:7462-7469.
34. Lee K-W, Kim SG, Kim H-P, Kwon E, You J, Choi H-J, Park J-H, Kang B-C, Im S-A, Kim T-Y. Enzastaurin, a protein kinase Cβ inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res. 2008; 68:1916-1926.
35. Swannie HC, Kaye SB. Protein kinase C inhibitors. Curr Oncol Rep. 2002; 4:37-46.
36. Guarracino F, Landoni G, Tritapepe L, Pompei F, Leoni A, Aletti G, Scandroglio AM, Maselli D, De Luca M, Marchetti C. Myocardial damage prevented by volatile anesthetics: a multicenter randomized controlled study. J Cardiothorac Vasc Anesth. 2006; 20:477-483.
37. Lee M-C, Chen C-H, Kuo M-C, Kang P-L, Lo A, Liu K. Isoflurane preconditioning-induced cardio-protection in patients undergoing coronary artery bypass grafting. Eur J Anaesthesiol. 2006; 23:841-847.
38. De Hert S, Vlasselaers D, Barbe R, Ory JP, Dekegel D, Donnadonni R, Demeere JL, Mulier J, Wouters P. A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery. Anaesthesia. 2009; 64:953-960.
39. Mentzer Jr RM, Birjiniuk V, Khuri S, Lowe JE, Rahko PS, Weisel RD, Wellons HA, Barker ML, Lasley RD and Investigators AMP. Adenosine myocardial protection: preliminary results of a phase II clinical trial. Ann Surg. 1999; 229:643.
40. Jin Z, Duan W, Chen M, Yu S, Zhang H, Feng G, Xiong L, Yi D. The myocardial protective effects of adenosine pretreatment in children undergoing cardiac surgery: a randomized controlled clinical trial. Eur J Cardiothorac Surg. 2011; 39:e90-e96.
41. Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry. 2000; 57:95-97.
42. Zarate CA, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA, Manji HK. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 2007; 9:561-570.
43. Yildiz A, Guleryuz S, Ankerst DP, Öngür D, Renshaw PF. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry. 2008; 65:255-263.
44. Mackay HJ, Twelves CJ. Targeting the protein kinase C family: are we there yet? Nat Rev Cancer. 2007; 7:554-562.
45. Zhang L, Cao F, Wang Y, Meng F, Zhang Y, Zhong D, Zhou Q. The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials. Clin Transl Oncol. 2014:1-7.
46. Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller CJ, Furnari FB. Cancer-Associated Protein Kinase C Mutations Reveal Kinase's Role as Tumor Suppressor. Cell. 2015; 160:489-502.
47. Dowling CM, Ors CH, Kiely PA. Using real-time impedancebased assays to monitor the effects of fibroblast-derived media on the adhesion, proliferation, migration and invasion of colon cancer cells. Biosci Rep. 2014; 34:415-427.
48. Pietras K, Östman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res. 2010; 316:1324-1331.
49. Nezhat F, Wadler S, Muggia F, Mandeli J, Goldberg G, Rahaman J, Runowicz C, Murgo AJ, Gardner GJ. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecol Oncol. 2004; 93:144-148.
50. Szallasi Z, Smith CB, Pettit GR, Blumberg PM. Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J Biol Chem. 1994; 269:2118-2124.
51. Dowling CM, Kiely PA. Targeting Protein Kinase C Downstream of Growth Factor, Adhesion Signalling. Cancers. 2015; 7:1271-1291.
52. Hanahan D, Weinberg Robert A. Hallmarks of Cancer: The Next Generation. Cell. 144:646-674.
53. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005; 9:59.
54. Wang M-T, Holderfield M, Galeas J, Delrosario R, To MD, Balmain A, McCormick F. K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling. Cell. 2015; 163:1237-1251.
55. Gallegos LL, Kunkel MT, Newton AC. Targeting protein kinase C activity reporter to discrete intracellular regions reveals spatiotemporal differences in agonist-dependent signaling. J Biol Chem. 2006; 281:30947-30956.
56. Kunkel MT, Ni Q, Tsien RY, Zhang J, Newton AC. Spatiotemporal dynamics of protein kinase B/Akt signaling revealed by a genetically encoded fluorescent reporter. J Biol Chem. 2005; 280:5581-5587.